Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation

Inclusion Criteria: 1. Recipients, adults of the first living or deceased donor kidney transplant; 2. Patients who agreed to participate in the study and signed the informed consent form Exclusion Criteria: 1. Receptors with a medical history of nephrotic syndrome or focal and segmental glomerulosclerosis confirmed as the etiology of end-stage renal disease; 2. Receptors with poor understanding about chronic kidney disease and its treatment alternatives; 3. Receptors with early history of non compliance to treatment with immunosuppressive drugs; 4. Retransplantation; 5. Multi-organ recipients; 6. Recipients with BMI\> 30 kg / m2; 7. KDPI\> 80%; 8. Cold ischemia time greater than 24 hours; 9. Receptors with a percentage of anti-HLA antibodies above 50%, either class I or Class II; 10. Women of childbearing potential who do not undertake contraceptive methods (condoms or oral contraceptives). 11. Patients receiving immunosuppressive therapy prior to transplantation, except low dose of prednisone; 12. Patients with severe uncontrolled dyslipidemia; 13. Patients who have a known contraindication for administration of any of the immunosuppressive drugs provided for in this study;